Digital Immunophenotyping Predicts Disease Free and Overall Survival in Early Stage Melanoma Patients

被引:6
|
作者
De Logu, Francesco [1 ]
Galli, Francesca [2 ]
Nassini, Romina [1 ]
Ugolini, Filippo [3 ]
Simi, Sara [3 ]
Cossa, Mara [4 ]
Miracco, Clelia [5 ]
Gianatti, Andrea [6 ]
De Giorgi, Vincenzo [7 ]
Rulli, Eliana [2 ]
Cossu, Antonio [8 ]
Massi, Daniela [3 ]
Mandala, Mario [9 ,10 ]
机构
[1] Univ Florence, Dept Hlth Sci, Sect Clin Pharmacol & Oncol, I-50100 Florence, Italy
[2] Ist Ric Farmacol Mario Negri IRCCS, Oncol Dept, Methodol Clin Res Lab, I-20156 Milan, Italy
[3] Univ Florence, Dept Hlth Sci, Sect Pathol Anat, I-50100 Florence, Italy
[4] Fdn IRCCS Ist Nazl Tumori, Dept Pathol, I-20133 Milan, Italy
[5] Univ Siena, Dept Med Surg & Neurosci, Unit Pathol Anat, I-53100 Siena, Italy
[6] Papa Giovanni XXIII Hosp, Pathol Unit, I-24127 Bergamo, Italy
[7] Univ Florence, Dermatol Unit, I-50100 Florence, Italy
[8] Univ Sassari, Sect Pathol, Dept Med Surg & Expt Sci, I-07100 Sassari, Italy
[9] Papa Giovanni XXIII Hosp, Div Pathol Anat, I-24127 Bergamo, Italy
[10] Univ Perugia, Unit Med Oncol, I-06123 Perugia, Italy
关键词
melanoma; digital pathology; tumor infiltrating lymphocytes;
D O I
10.3390/cells10020422
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: the prognostic significance of tumor infiltrating lymphocytes (TILs) in intermediate/thick primary cutaneous melanoma (PCM) remains controversial, partially because conventional evaluation is not reliable, due to inter-observer variability and diverse scoring methods. We aimed to assess the prognostic impact of the density and spatial distribution of immune cells in early stage intermediate/thick PCM. Materials and Methods: digital image acquisition and quantitative analysis of tissue immune biomarkers (CD3, CD4, CD8, CD68, PD-L1, CD163, FOX-P3, and PD-1) was carried out in a training cohort, which included patients with primary PCM >= 2 mm diagnosed, treated, and followed-up prospectively in three Italian centers. Results were validated in an independent Italian cohort. Results: in the training cohort, 100 Stage II-III melanoma patients were valuable. At multivariable analysis, a longer disease free survival (DFS) was statistically associated with higher levels of CD4(+) intratumoral T-cells (aHR [100 cell/mm(2) increase] 0.98, 95%CI 0.95-1.00, p = 0.041) and CD163(+) inner peritumoral (aHR [high vs. low] 0.56, 95%CI 0.32-0.99, p = 0.047). A statistically significant longer DFS (aHR [high-high vs. low-low] 0.52, 95%CI 0.28-0.99, p = 0.047) and overall survival (OS) (aHR [high-high vs. low-low] 0.39, 95%CI 0.18-0.85, p = 0.018) was found in patients with a high density of both intratumoral CD8(+) T-cells and CD68(+) macrophages as compared to those with low density of both intratumoral CD8(+) T-cells and CD68(+) macrophages. Consistently, in the validation cohort, patients with high density of both intratumoral CD8(+) and CD3(+) T-cells were associated to a statistically better DFS (aHR[high-high vs. low-low] 0.24, 95%CI 0.10-0.56, p < 0.001) and those with high density of both intratumoral CD8(+) and CD68(+) were associated to a statistically longer OS (aHR[high-high vs. low-low] 0.28, 95%CI 0.09-0.86, p = 0.025). Conclusion: our findings suggest that a specific preexisting profile of T cells and macrophages distribution in melanomas may predict the risk of recurrence and death with potential implications for the stratification of stage II-III melanoma patients.
引用
收藏
页码:1 / 20
页数:19
相关论文
共 50 条
  • [1] Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma
    Brozyna, Anna A.
    Jozwicki, Wojciech
    Carlson, J. Andrew
    Slominski, Andrzej T.
    HUMAN PATHOLOGY, 2013, 44 (10) : 2071 - 2074
  • [2] Effect of chemotherapy in patients with early stage synovial sarcoma on disease-free survival or overall survival.
    Pan, Minggui
    Merchant, Maqdooda
    Habel, Laurel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] The preoperative neutrophil to lymphocyte ratio predicts disease-free survival and overall survival in patients with stage II and III colon cancer
    Absenger, G.
    Szkandera, J.
    Weissmueller, M.
    Postlmayr, U.
    Pichler, M.
    Loibner, H.
    Samonigg, H. S.
    Gerger, A.
    ONKOLOGIE, 2012, 35 : 55 - 56
  • [4] Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
    Varey, Alexander H. R.
    Li, Isabel
    El Sharouni, Mary-Ann
    Simon, Julie
    Dedeilia, Aikaterini
    Ch'ng, Sydney
    Saw, Robyn P. M.
    Spillane, Andrew J.
    Shannon, Kerwin F.
    Pennington, Thomas E.
    Rtshiladze, Michael
    Stretch, Jonathan R.
    Nieweg, Omgo E.
    van Akkooi, Alexander
    Sullivan, Ryan J.
    Boland, Genevieve M.
    Gershenwald, Jeffrey E.
    van Diest, Paul J.
    Scolyer, Richard A.
    Long, Georgina V.
    Thompson, John F.
    Lo, Serigne N.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (10) : 1169 - 1180
  • [5] Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI)
    Mandala, Mario
    Galli, Francesca
    Patuzzo, Roberto
    Maurichi, Andrea
    Mocellin, Simone
    Rossi, Carlo R.
    Rulli, Eliana
    Montesco, Maria
    Quaglino, Pietro
    Caliendo, Virginia
    De Giorgi, Vincenzo
    Merelli, Barbara
    Caraco, Corrad
    Piazzalunga, Dario
    Labianca, Alice
    Ribero, Simone
    Senetta, Rebecca
    Gianatti, Andrea
    Valeri, Barbara
    Massi, Daniela
    Ascierto, Paolo A.
    Santinami, Mario
    EUROPEAN JOURNAL OF CANCER, 2020, 137 : 30 - 39
  • [6] Obesity is not associated with disease-free interval, melanoma-specific survival, or overall survival in patients with clinical stage IB-II melanoma after SLNB
    Deckers, Eric A.
    Kruijff, Schelto
    Bastiaannet, Esther
    van Ginkel, Robert J.
    Hoekstra-Weebers, Josette E. H. M.
    Hoekstra, Harald J.
    JOURNAL OF SURGICAL ONCOLOGY, 2021, 124 (04) : 655 - 664
  • [7] Disease-free and overall survival outcomes for localized RCC patients by disease stage.
    Haas, Naomi B.
    Bhattacharya, Rituparna
    Ogbomo, Adesuwa S.
    Imai, Kentaro
    Gautam, Santosh
    Rogerio, Jackie
    Yu, Rebekah
    Chhabra, Jatin
    Sundaram, Murali
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16526 - E16526
  • [8] Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma
    Schmidt, H
    Johansen, JS
    Sjoegren, P
    Christensen, IJ
    Sorensen, BS
    Fode, K
    Larsen, J
    von der Maase, H
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (05) : 798 - 804
  • [9] Improving Survival for Patients With Early-Stage Melanoma
    Maher, Ian A.
    JAMA DERMATOLOGY, 2019, 155 (11) : 1229 - 1230
  • [10] Tumor iNOS predicts poor survival for stage III melanoma patients
    Ekmekcioglu, Suhendan
    Ellerhorst, Julie A.
    Prieto, Victor G.
    Johnson, Marcella M.
    Broemeling, Lyle D.
    Grimm, Elizabeth A.
    INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (04) : 861 - 866